Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept 8 mg PFS in DME or nAMD
NCT05989126Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Apr 2024
- Primary completion
- May 2024
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of aflibercept in diabetic macular edema (DME) and neovascular age-related macular degeneration (NVAMD), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Number of 8 mg Aflibercept Injections Successfully Administered Utilizing the PFS at Day 1. Started Apr 2024; status: completed.
02
Drugs
aflibercept
03
Conditions
diabetic macular edema (DME)neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT05989126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05989126.